Inogen Inc (INGN) 58.11 $INGN Inogen Hits 52-Week High

New Post Public Reply Private Reply Replies (0) Message Board

Sep 4, 2016 at 7:04 AM

Inogen Inc (INGN) 58.11 $INGN

Inogen Hits 52-Week High on Solid Q2 & Estimate Revision
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:01AM CDT
Share price of Inogen Inc (INGN) rallied to a new 52-week high of $59 on Aug 30, eventually closing a tad bit lower at $58.46.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), INGN: 58.11 (+0.16), NUVA: 66.74 (+0.68)

Inogen One G4 Cleared for Onboard Use, Market Hold Strong
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:17AM CDT
Inogen recently announced that its One G4 received an approval for an exclusive use on commercial flights.
MASI: 59.90 (+0.47), INGN: 58.11 (+0.16), IDXX: 114.09 (+0.93), CRY: 16.23 (+0.39)

Inogen Broadens Market Access and Patient Travel Options
BusinessWire - Mon Aug 22, 3:01PM CDT
Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that its innovative Inogen One G4 portable oxygen concentrator is now allowed for use onboard commercial aircraft and the start of the domestic business-to-business sales channel launch. The launch of the Inogen One G4 in the domestic business-to-business sales channel will consist of a phased approach that is expected to take place throughout the third quarter.
INGN: 58.11 (+0.16)

Inogen (INGN) Beats Q2 Earnings & Revenues, FY16 View Up
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 2:43PM CDT
Inogen reported second-quarter 2016 earnings of 25 cents per share, which surpassed the Zacks Consensus Estimate by 6 cents.
MASI: 59.90 (+0.47), INGN: 58.11 (+0.16), IDXX: 114.09 (+0.93), MLAB: 112.17 (-1.21)

Inogen Announces Second Quarter 2016 Financial Results
BusinessWire - Thu Aug 04, 3:05PM CDT
--- Q2 2016 Sales Revenue up 40.7% Over the Same Period in 2015 -
INGN: 58.11 (+0.16)

Inogen (INGN) Q2 Earnings: Can the Stock Pull a Surprise?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 8:54AM CDT
Inogen Inc. (INGN) is scheduled to report second-quarter 2016 results on Aug 4.
ZTS: 51.26 (+0.15), ANIP: 59.86 (-1.56), INGN: 58.11 (+0.16), GLYC: 7.25 (-0.18)

Top Stocks with Big Potential Catch-Up Moves
Kevin Matras - ZACKS - Tue Jul 26, 2:31PM CDT
Top Stocks with Big Potential Catch-Up Moves
CSGP: 213.05 (+2.97), CW: 91.12 (+1.00), INGN: 58.11 (+0.16), HLS: 40.81 (+0.61), PKI: 53.46 (+0.20)

Inogen Announces Participation in 36th Annual William Blair Growth Stock Conference
BusinessWire - Wed Jun 01, 3:05PM CDT
Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that the Company will be participating in the 36th Annual William Blair Growth Stock Conference.
INGN: 58.11 (+0.16)

Inogen (INGN) Introduces Next-Gen Inogen One G4 POC
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:15AM CDT
Inogen Inc (INGN) recently launched a next-generation portable oxygen concentrator (POC) -- Inogen One G4.
MASI: 59.90 (+0.47), INGN: 58.11 (+0.16), EXAC: 27.90 (+0.10), CRY: 16.23 (+0.39)

Inogen Releases Innovative Inogen One G4(TM) Oxygen Concentrator
BusinessWire - Tue May 31, 7:00AM CDT
Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the release to market of its innovative Inogen One G4 portable oxygen concentrator. The ultra-portable device is the smallest and lightest oxygen concentrator that the Company has ever produced, and the Company expects the product to be embraced by long-term oxygen therapy users worldwide.
INGN: 58.11 (+0.16)

Inogen Announces Investor/Analyst Day and Webcast
BusinessWire - Tue May 24, 6:30AM CDT
Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced it will host an institutional investor and analyst meeting on Tuesday, June 7, 2016 in Los Angeles, CA, from 1:00 p.m. to 3:30 p.m. PT. The meeting will include presentations from company executives and Vernon Pertelle, President and CEO of StratiHealth and President and Executive Director of Pulmonary Horizons Health, an industry expert in homecare respiratory therapy.
INGN: 58.11 (+0.16)

Inogen misses 1Q profit forecasts
Automated Insights - Mon May 09, 3:25PM CDT
GOLETA, Calif. (AP) _ Inogen Inc. (INGN) on Monday reported first-quarter net income of $2.4 million.
INGN: 58.11 (+0.16)

Inogen Announces First Quarter 2016 Financial Results
BusinessWire - Mon May 09, 3:05PM CDT
--- Q1 2016 Net Income up 50.4% Over the Same Period in 2015 -
INGN: 58.11 (+0.16)

Med Instruments Stocks' Q1 Earnings: PEN, INGN, OPKO, NVRO
Zacks Equity Research - Zacks Investment Research - Fri May 06, 8:33AM CDT
Watch out for Medical Instrument stocks PEN, INGN, OPKO and NVRO reporting first-quarter results on May 9.
OPK: 9.33 (+0.04), INGN: 58.11 (+0.16), PEN: 70.63 (+0.61), NVRO: 95.91 (-0.11)

Inogen (INGN) Q1 Earnings: What's in Store for the Stock?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 5:51PM CDT
Inogen Inc. (INGN) is scheduled to report first-quarter 2016 results on May 9
XON: 25.33 (+0.04), INGN: 58.11 (+0.16), QSII: 11.86 (+0.08), COO: 185.92 (+0.55)

DexCom (DXCM) Q1 Loss Wider than Expected, Stock Down
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:46AM CDT
Shares of DexCom Inc. (DXCM) fell 3.6% to close at $65.96 on Apr 28, following a disappointing first-quarter 2016 earnings release.
ANTM: 124.24 (+0.88), DXCM: 92.09 (+0.38), INGN: 58.11 (+0.16), EXAC: 27.90 (+0.10)

Inogen Announces Updated Time for First Quarter 2016 Results Earnings Conference Call - Monday, May 9, 2016, 2:30 PM PT / 5:30 PM ET
BusinessWire - Thu Apr 28, 3:01PM CDT
Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that the previously announced conference call with management to discuss first quarter 2016 results will now be held at 2:30pm PT/5:30pm ET on Monday, May 9, 2016. Results for the quarter will be released after the market closes on the same day.
INGN: 58.11 (+0.16)

Varian (VAR) Beats Q2 Earnings by a Penny, Lags Revenues
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 8:19AM CDT
Varian Medical Systems Inc. (VAR) reported earnings of $1.09 per share in the second quarter of fiscal 2016, which beat the Zacks Consensus Estimate by a penny.
RTIX: 3.40 (+0.08), VAR: 96.41 (+0.52), INGN: 58.11 (+0.16), EXAC: 27.90 (+0.10)

Accuray (ARAY) Posts Earnings in Q3, Down on View Cut
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 10:55AM CDT
Shares of Accuray Inc. (ARAY) fell 3.3% in after-hours trading following the company's third-quarter fiscal 2016 results and trimmed fiscal 2016 guidance.
INGN: 58.11 (+0.16), EXAC: 27.90 (+0.10), ARAY: 5.42 (+0.12), HOLX: 38.51 (+0.05)

Pacific Biosciences (PACB) Q1 Loss Narrower than Expected
Zacks Equity Research - Zacks Investment Research - Fri Apr 22, 7:21AM CDT
Pacific Biosciences of California Inc. (PACB) reported a decent first-quarter 2016, thanks to the growing demand for its new Sequel system.
PACB: 8.28 (-0.02), GMED: 23.97 (+0.51), INGN: 58.11 (+0.16), EXAC: 27.90 (+0.10)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

WHO and RCSI Bahrain Join Forces on Health Initiatives

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

BETR's Slide: Investors Face Big Losses, Leadership Shift

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...